Develop and validate bespoke models tailored to your criteria
We offer stand-alone in vitro assays to investigate efficacy against a wide range of bacterial and fungal pathogens. With expertise in efficacy models, pharmacokinetic (PK) models, and safety models, you can count on quality studies with accelerated data delivery.
In vivo models of infection
- Aspergillus lung infection, mouse
- Candida Albicans sepsis, mouse
- Hepatitis B virus (HBV), mouse
- AAV-HBV, HBV/HDV, HBV mutant
- HBV infected human liver chimeric mouse model (PXB® mice)
- Influenza (H1N1), mouse/ferret
- Methicillin-resistant Staphylococcus aureus (MRSA) Neutropenic thigh infection PK/PD model, rat
- Pseudomonas aeruginosa lung infection, mouse
- Respiratory syncytial virus (RSV) lung infection, mouse
- Streptococcus pneumoniae lung infection, mouse
- Streptococcus pneumoniae sepsis model, mouse
In vivo study support services
- Preparation of bacterial/viral/fungal infective doses, including agar bead prep for bacterial and fungal respiratory models
- Organ/tissue bioburden counts
- Viral titre assays (CPE assay, Plaque assay)
- Bacteriophage plaque assays
In vitro antimicrobial efficacy
- In vitro Minimum Inhibitory Concentration (MIC) assays
- Aerobic/anaerobic bacteria and fungal pathogens (Hazard class 2)
- Antibiotic resistance/susceptibility testing
Non-animal model for assessment of acute toxicity and antimicrobial efficacy
- Galleria mellonella wax moth larva model - TruLarvTM